Navigation Links
Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug
Date:3/20/2013

BEER-SHEVA, Israel, March 20, 2013 -- Ben-Gurion University of the Negev (BGU) researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis. The finding was reported in a new paper published in Chemistry and Biology.

Psoriasis is a chronic, non-contagious disease characterized by inflamed lesions covered with silvery-white scabs of dead skin. An auto-immune disease, psoriasis affects at least four million Americans. It is caused by the disturbance in the natural balance between pro-inflammatory signals and signals that inhibit inflammation.

One of the key signals involved in the progression of psoriasis is the immune system protein Interleukin 17 (IL-17). The research team developed a method to inhibit IL-17 pro-inflammatory signals and proved that their engineered receptor, IL-17R, is highly effective in reducing IL-17 induced inflammatory signals in mice models. Moreover, injection of the receptor into a mouse model with acute human psoriasis eliminated the symptoms, essentially curing the disease.

"Using directed evolution to improve the properties of the IL-17 receptor, we have created engineered mutants that might prove there is a viable treatment for patients with severe psoriasis that do not respond to current drugs," explains Dr. Amir Aharoni, one of the researchers in BGU's Department of Life Sciences and the National Institute for Biotechnology in the Negev.

"Since the directed evolution method can be applied to other receptors involved in autoimmune diseases and cancer, I believe that we are just starting to unravel the potential of this approach," Aharoni adds.

Directed evolution is an iterative Darwinian optimization process used in protein engineering whereby the fittest variants are selected from a collection of random mutations. Improved variants are identified and isolated by screening or selection for the property of interest. This approach is particularly advantageous in cases in which no prior knowledge of a protein's mechanism and structure is available.

The other researchers credited in "Directed Evolution of a Soluble Human IL-17A Receptor for the Inhibition of Psoriasis Plaque Formation in a Mouse Model" are BGU's Dr. Marianna Zaretsky and Teva researchers Dr. Liora Sklair-Tavron, Dr. Joel Kaye and Revital Etzyoni.


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Related biology news :

1. Ben-Gurion U. establishes stem cell research fund in honor of inventor Jordan Baruch
2. Ben-Gurion University team in prestigious DARPA Robotics Challenge to develop disaster response robot
3. Preeclampsia poses a significant long-term health risk according to new research from Ben-Gurion U.
4. Ben-Gurion University of the Negev receives $450,000 grant to conduct oil and natural gas research
5. Sleep deprivation may reduce risk of PTSD according to Ben-Gurion U. researchers
6. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
7. Dartmouth researchers invent real time secondhand smoke sensor
8. UMass Amherst researchers reveal mechanism of novel biological electron transfer
9. Researchers create map of shortcuts between all human genes
10. Researchers divide enzyme to conquer genetic puzzle
11. Researchers building stronger, greener concrete with biofuel byproducts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition ... Service, Application Area, End User, And Region - Global Forecast to 2021", published ... in 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci, in ... its customers three new solutions for measurements where traditional cuvette applications are not ... customer has an oddly-shaped sample that would not fit into a typical cuvette ...
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... enhanced the platform to accommodate increasingly complex and sophisticated deployments, resulting in ... more. In addition to these improvements, the latest release brings enhanced data ...
(Date:1/11/2017)... YORK , Jan. 11, 2017  Brian Mehling, ... and founder of Blue Horizon International (BHI), will be ... Davos from January 17-20, 2017. ... global conference. The theme of this year,s ... the program,s 400 sessions will address strategies for fostering ...
Breaking Biology Technology: